Home/Pipeline/Ulixacaltamide (PRAX-944)

Ulixacaltamide (PRAX-944)

Essential Tremor

Phase 3ActiveEssential3

Key Facts

Indication

Essential Tremor

Phase

Phase 3

Status

Active

Company

Praxis Precision Medicines

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biotech company with a mission to revolutionize neurology by developing precision therapies for CNS disorders, leveraging a proprietary platform built on human genetics, translational tools, patient-guided development, and rigorous clinical paths. The company has achieved significant valuation growth, driven by a promising pipeline targeting rare genetic epilepsies, essential tremor, and focal seizures, with multiple late-stage clinical programs underway. Its strategy focuses on de-risking development through genetic validation and efficient trial designs to address devastating, high-unmet-need conditions.

View full company profile

Therapeutic Areas

Central Nervous System (CNS) Disorders Epilepsy Movement Disorders

Other Essential Tremor Drugs

Drug	Company	Phase	Status
SAGE-324	Sage Therapeutics	Phase 2	Active
Platform Expansion	Rune Labs	Research	Active
Exablate Neuro	Insightec	Approved	Active
Felix NeuroAI™ Wristband	Fasikl	Approved	Active
GABA-A PAM for Essential Tremor	Modulate Bio	Preclinical	Active